Currency In USD
| Previous Close | 5.53 |
| Open | 5.48 |
| Day High | 5.48 |
| Day Low | 5.12 |
| 52-Week High | 25.96 |
| 52-Week Low | 4.81 |
| Volume | 75,807.31 |
| Average Volume | 955,729 |
| Market Cap | 194.5M |
| PE | -2.17 |
| EPS | -2.38 |
| Moving Average 50 Days | 7.97 |
| Moving Average 200 Days | 16.17 |
| Change | -0.36 |
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 9:30 PM GMT
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of hu
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
GlobeNewswire Inc.
Jan 22, 2026 3:30 AM GMT
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o
BioAge Announces Proposed Public Offering
GlobeNewswire Inc.
Jan 20, 2026 9:01 PM GMT
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology o